Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

recurrent non-small cell lung cancerextensive stage small cell lung cancerrecurrent small cell lung cancerstage IIIB non-small cell lung cancerstage IV non-small cell lung cancerlung metastasesbronchoalveolar cell lung cancer

Interventions

doxorubicin hydrochlorideDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically confirmed primary lung cancer or cancer metastatic to the lung that is not potentially curable by standard chemotherapy, radiotherapy, or surgery * Bronchoalveolar cell lung cancer allowed * Lung metastases from soft tissue sarcoma allowed * No leukemia or lymphoma PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 70-100% Life expectancy: * Not specified Hematopoietic: * WBC at least 4,000/mm\^3 * Platelet count at least 160,000/mm\^3 * Hemoglobin at least 9 g/dL Hepatic: * Bilirubin no greater than 1.0 mg/dL * AST/ALT less than 1.5 times upper limit of normal Renal: * Creatinine no greater than 1.2 mg/dL OR * Creatinine clearance at least 50 mL/min Cardiovascular: * LVEF normal by MUGA scan or echocardiography * No unstable angina * No congestive heart failure * No symptomatic arrhythmias Pulmonary: * DLCO at least 65% of normal * FVC at least 50% predicted * FEV1 at least 50% predicted * Resting oxygen saturation at least 90% * Exercise oxygen saturation at least 85% * No complete atelectasis * No asthma Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after study * No congenital problems (e.g., cleft palate) or other anomalies that would prevent tight fit of mouth seal * No other concurrent illness that would preclude study therapy PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Disease Characteristics * At least 3 weeks since prior chemotherapy and recovered * No prior bleomycin or nitrosoureas * No prior mitomycin greater than 25 mg/m\^2 * No prior anthracyclines greater than 450 mg/m\^2 * No other concurrent chemotherapy Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * At least 3 weeks since prior radiotherapy and recovered * No prior chest (pulmonary or mediastinal) or thoracic spine radiotherapy * Patients with only chest wall or primary breast radiation are eligible * No concurrent thoracic irradiation Surgery: * See Disease Characteristics * No prior pneumonectomy Other: * No daily or as necessary respiratory drugs via inhaler or nebulizer * No other concurrent experimental drugs

Sponsors & Collaborators

Memorial Sloan Kettering Cancer Center
Otherlead
National Cancer Institute (NCI)
NIHcollaborator

Study Sites (2)

Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States

Arthur G. James Cancer Hospital - Ohio State University

Columbus, Ohio, 43210, United States

MeSH Terms

Conditions

Lung NeoplasmsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaAdenocarcinoma, Bronchiolo-Alveolar

Interventions

Doxorubicin

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesNeoplastic ProcessesPathologic Processes

Study Officials

Naiyer Rizvi, MD
Memorial Sloan Kettering Cancer Center
STUDY CHAIR

Study Design

Study Type: interventional
Phase: phase 1
Purpose: TREATMENT
Sponsor Type: OTHER

Study Record Dates

First Submitted

March 7, 2000

First Posted

January 27, 2003

Study Start

July 1999

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

February 2004

Actual (reported)

Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations